Abstract #0844

Caffeine and brain development in preterm children

Claire Kelly^1,2, Wenn Lynn Ooi^1,2, Joseph Yuan-Mou Yang^2,3,4, Jian Chen^2,5, Chris Adamson², Katherine Lee^6,7, Jeanie Cheong^1,8,9, Peter Anderson^1,7,10, Lex Doyle^1,7,8,9, and Deanne Thompson^1,2,7,11

¹Victorian Infant Brain Studies, Murdoch Children's Research Institute, Melbourne, Australia, ²Developmental Imaging, Murdoch Children's Research Institute, Melbourne, Australia, ³Department of Neurosurgery, The Royal Children's Hospital, Melbourne, Australia, ⁴Neuroscience research, Murdoch Children's Research Institute, Melbourne, Australia, ⁵Department of Medicine, Monash Medical Centre, Monash University, Melbourne, Australia, ⁶Clinical Epidemiology and Biostatistics Unit, Murdoch Children's Research Institute, Melbourne, Australia, ⁷Department of Paediatrics, The University of Melbourne, Melbourne, Australia, ⁸Newborn research, The Royal Women's Hospital, Melbourne, Australia, ⁹Department of Obstetrics and Gynaecology, The University of Melbourne, Melbourne, Australia, ¹⁰Monash Institute of Cognitive and Clinical Neurosciences, Monash University, Melbourne, Australia, ¹¹Florey Institute of Neuroscience and Mental Health, Melbourne, Australia

We investigated effects of neonatal caffeine treatment on brain structure and longitudinal development in a subset of preterm children from a randomized, placebo-controlled trial. Children had MRI at age 11 years (n=118; 64 received caffeine, 54 received placebo), of whom 43 (21 caffeine, 22 placebo) had MRI at term-equivalent age. Global and regional brain volumes, cortical morphometry and white matter microstructure were similar between treatment groups at age 11 years, as was brain development from term-equivalent age to 11 years of age. Any benefits of caffeine on brain structure weaken over time and were not apparent at age 11 years.

This abstract and the presentation materials are available to members only; a login is required.

Join Here